Dyskinesia: Research and Treatment (Psychopharmacology Series, 2)

critically reviewed. Finally, data about antiparkinson drug-induced dyskinesias, as well as idiopathic dystonia and other dyskinesias, contribute additional perspectives to questions surrounding tardive dyskinesia. Front Matter....Pages I-IX Front Matter....Pages 1-1 Brain Dopamine Receptors in Schizophrenia and Tardive Dyskinesia....Pages 2-8 Receptor-Binding Profiles of Neuroleptics....Pages 9-18 Functional Classification of Different Dopamine Receptors....Pages 19-30 Pharmacological Properties of Presynaptic Dopamine Receptor Agonists....Pages 31-38 Influence of GABA Mimetics and Lithium on Biochemical Manifestations of Striatal Dopamine Target Cell Hypersensitivity....Pages 39-45 New Aspects on the Role of Dopamine, Acetylcholine, and GABA in the Development of Tardive Dyskinesia....Pages 46-57 Differential Effects of Dopamine D-1 and D-2 Agonists and Antagonists in 6-Hydroxydopamine-Lesioned Rats....Pages 60-61 Front Matter....Pages 63-63 Is Tardive Dyskinesia a Unique Disorder?....Pages 64-71 Tardive Dyskinesia: Prevalence, Incidence, and Risk Factors....Pages 72-78 Involuntary Disorders of Movement in Chronic Schizophrenia — The Role of the Illness and Its Treatment....Pages 79-87 Tardive Dyskinesia: Reversible and Irreversible....Pages 88-97 Pathophysiological Mechanisms Underlying Tardive Dyskinesia....Pages 98-103 Chemical and Structural Changes in the Brain in Patients with Movement Disorder....Pages 104-110 Medical Treatment of Dystonia....Pages 111-117 The Effect of Dopamine Antagonists in Spontaneous and Tardive Dyskinesia....Pages 118-121 GABA Dysfunction in the Pathophysiology of Tardive Dyskinesia....Pages 122-127 Clinical Activity of GABA Agonists in Neuroleptic- and L -Dopa-Induced Dyskinesia....Pages 128-136 Tardive Dyskinesia: Nondopaminergic Treatment Approaches....Pages 137-144 Pathophysiology of L -Dopa-Induced Abnormal Involuntary Movements....Pages 145-159 Prevalence of Tardive Dyskinesia in a Clinic Population....Pages 162-172 Front Matter....Pages 173-173 Differential Alteration of Striatal D-1 and D-2 Receptors Induced by the Long-Term Administration of Haloperidol, Sulpiride or Clozapine to Rats....Pages 174-181 Pharmacological Differentiation of Dopamine D-1 and D-2 Antagonists After Single and Repeated Administration....Pages 182-190 Pathophysiology of Tardive Dyskinesia....Pages 191-193 Intermittent Treatment with Droperidol, a Short-Acting Neuroleptic, Increases Behavioral Dopamine Receptor Sensitivity....Pages 194-199 Induction and Reversal of Dopamine Dyskinesia in Rat, Cat, and Monkey....Pages 200-210 Behavioral Effects of Long-Term Neuroleptic Treatment in Cebus Monkeys....Pages 211-216 Induction of Tardive Dyskinesia in Cebus apella and Macaca speciosa Monkeys: A Review....Pages 217-223 Back Matter....Pages 225-230 More than a quarter century has passed since the initial descriptions of tardive dyskinesia (Schonecker, 1957; Sigwald et aI., 1959). The earliest epidemiologic study of this disorder was carried out in Roskilde, Denmark, by Uhrbrand and Faurbye (1960); the term tardive dyskinesia was first used a few years later in a subsequent paper (Faurbye et aI., 1964). Despite 25 years of intensive investiga tive scrutiny, the syndrome persists, and approaches to its prevention and treat ment continue to have limited efficacy. It is thus fitting to evaluate what has already been learned and consider future directions for research. . Tardive dyskinesia is generally dermed as an involuntary movement disorder, mainly involving the mouth, which attends long-term neuroleptic exposure. Beyond these simple facts, however, there has been relatively little consensus about this disorder. A desire to address the controversies associated with tardive dyskinesia prompted the organization of an international symposium at Kolle kolle, just outside Copenhagen. This publication comprises all 26 presentations Papers Presented at an International Symposium, Held in 1984 at Kollekolle, Denmark